Table 2.
Treatment for pancreatic neuroendocrine neoplasms
| Overall (n = 78) no. (%) | PNET (n = 64) no. (%) | PNEC (n = 14) no. (%) | |
|---|---|---|---|
| Targeted therapy | 53 (68) | 47 (73) | 6 (43) |
| Everolimus | 50 (64) | 45 (70) | 5 (36) |
| Sunitinib | 23 (29) | 20 (31) | 3 (21) |
| Somatostatin analog | 47 (60) | 43 (67) | 4 (29) |
| Chemotherapy | 40 (51) | 29 (45) | 11 (79) |
| Platinum-based regimens | 19 (24) | 8 (13) | 11 (79) |
| GEM-based regimens | 18 (23) | 16 (25) | 2 (14) |
| 5-FU-based regimens | 13 (17) | 12 (19) | 1 (7) |
| STZ-based regimens | 8 (10) | 8 (13) | 0 |
| Others | 6 (8) | 5 (8) | 1 (7) |
| No. of regimens | |||
| 1 regimen | 24 (31) | 16 (25) | 8 (57) |
| 2 regimens | 12 (15) | 10 (16) | 2 (14) |
| ≥3 regimens | 4 (5) | 3 (5) | 1 (7) |
| Liver-directed therapy (TACE and/or RFA) | 31 (40) | 30 (47) | 1 (7) |
| 1–2 time | 21 (27) | 20 (31) | 1 (7) |
| 310 times | 7 (9) | 7 (11) | 0 |
| ≥11 times | 3 (4) | 3 (5) | 0 |
| Aggressive surgerya | 18 (23) | 17 (27) | 1 (7) |
| Pancreas | 11 (14) | 11 (17) | 0 |
| Liver | 5 (6) | 5 (8) | 0 |
| Others | 5 (6) | 4 (8) | 1 (7) |
| Radiation | 4 (5) | 4 (6) | 0 |
| PRRT | 3 (4) | 3 (5) | 0 |
| Others | 2 (3) | 2 (3) | 0 |
| Best supportive care | 1 (1) | 0 | 1 (7) |
| Unknown | 1 (1) | 1 (2) | 0 |
5-FU, 5-fluorouracil; GEM, gemcitabine; PRRT, peptide receptor radionuclide therapy; RFA, radiofrequency ablation; STZ, streptozocin; TACE, transarterial chemoembolization.
aNon-curative resection for primary site and/or metastatic sites.